Sesen Bio, Inc.

NasdaqCM:SESN Stock Report

Market Cap: US$2.6b

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Sesen Bio Future Growth

Future criteria checks 0/6

Key information

19.3%

Earnings growth rate

4.38%

EPS growth rate

Biotechs earnings growth24.3%
Revenue growth rate-85.7%
Future return on equityn/a
Analyst coverage

Low

Last updated28 Feb 2023

Recent future growth updates

Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Aug 12
Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Recent updates

Sesen Bio and Carisma Therapeutics announce merger agreement

Sep 21

Sesen Bio GAAP EPS of -$0.16 misses by $0.03

Aug 08

Sesen Bio granted additional time period for regaining compliance

Jul 27

Sesen Bio slips after decision to pause U.S. studies for lead asset

Jul 18

Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives

Jun 02

We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully

Apr 17
We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate

Dec 05
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate

Sesen Bio: Interesting Price Drop After CRL

Nov 24

Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022

Nov 17

Sesen Bio: The Road Ahead

Aug 23

Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Aug 12
Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat

Feb 18
News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat

Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Jan 26
Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook

Dec 21
Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook

Earnings and Revenue Growth Forecasts

NasdaqCM:SESN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2025N/A-9-18N/A1
12/31/2024N/A-8-8N/A1
12/31/2023N/A-26-20N/A1
12/31/202240-202525N/A
9/30/202260-31010N/A
6/30/20222048-29-29N/A
3/31/20222254-43-43N/A
12/31/2021270-69-69N/A
9/30/20217-24-65-65N/A
6/30/202118-118-54-54N/A
3/31/202116-119-40-40N/A
12/31/202011-23-31-31N/A
9/30/202011-41-36-36N/A
6/30/2020N/A-32-39-39N/A
3/31/2020N/A-60-39-38N/A
12/31/2019N/A-107-38-38N/A
9/30/2019N/A-81-32-31N/A
6/30/2019N/A-82-30-30N/A
3/31/2019N/A-36-26-26N/A
12/31/2018N/A-34-23-23N/A
9/30/2018N/A-33-19-19N/A
6/30/2018N/A-29-18-18N/A
3/31/2018N/A-27-17-17N/A
12/31/20170-29-18-18N/A
9/30/20171-26-20-20N/A
6/30/201730366N/A
3/31/201730366N/A
12/31/201630233N/A
9/30/201630-5N/A-1N/A
6/30/20161-34N/A-31N/A
3/31/20161-35N/A-35N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SESN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SESN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SESN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SESN is forecast to have no revenue next year.

High Growth Revenue: SESN is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SESN's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/03/08 08:58
End of Day Share Price 2023/03/07 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sesen Bio, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John NewmanCanaccord Genuity
Swayampakula RamakanthH.C. Wainwright & Co.
Christopher HowertonJefferies LLC